The US Food and Drug Administration gave emergency use authorisation to the Pfizer COVID-19 vaccine on 11 December after only 108 days of safety review. They then requested a federal court to delay release of the Pfizer trial data by 75 years, which was rejected in January 2022. They are required to release 55,000 pages per month and the documents are being shared for public view by Public Health and Medical Professionals for Transparency. The most recent release was on 2 May 2022.
As outlined previously, Vaccine Associated Enhanced Disease (VAED) is a complex biological response which occurs when a person is exposed to a virus they are vaccinated against, but for which they have generated deficient antibodies. Instead of blocking the virus from entering the person’s cells, these antibodies react upon exposure to the virus by assisting it into the cells. This results in more severe disease being seen in the vaccinated than those who have no virus-specific antibodies at all, or who have been infected previously and have robust natural immunity.
A form of VAED is Vaccine Associated Enhanced Respiratory Disease (VAERD), which has been known about since at least 1967 following attempts to introduce a vaccine against Respiratory Syncytial Virus (RSV). Described by Acosta et al in 2016, vaccinated infants and toddlers experienced an enhanced form of RSV disease when they were subsequently exposed to the virus and two children died.
VAED has been seen in other vaccine trials. As recently as 2017 a Dengue vaccine introduced in the Philippines (described by Michaeleen Doucleff in 2019) was associated with the deaths of 600 children. Multiple attempts to develop vaccines against other Coronaviruses such as SARS-CoV-1 and MERS (described by Padron-Regalado, 2020) have resulted in VAED outcomes.
It should come as no surprise that the risk of VAED was known by researchers involved in the Pfizer vaccine trials. What does seem surprising and of extreme concern, is the revelation that recently released Pfizer trial data shows evidence of VAED and VAERD occurring in 75 participants within the first three months after vaccinations began on 1 December 2020, resulting in 8 disabilities, 13 life-threatening events and 38 deaths.
Questioning the Honesty of Pfizer Trial Data Documents
The Exposé 4 May 2022 article Pfizer Documents reveal Medicine Regulators and Pfizer knew COVID Vaccine caused Vaccine-Associated Enhanced Disease uses UK government and Pfizer trial data documents to scrutinise this issue. Providing details of their information and calculations, they show that VAED is being seen amongst the double-vaccinated population in the UK. Negative vaccine effectiveness against hospitalisation is seen across all age groups, worsening with older age. Vaccine effectiveness against death has some weakly positive outcomes in younger age groups, but from 40 years and older effectiveness is negative, and worsens with older age.
Authors at The Exposé question Pfizer’s conclusions that VAED and VAERD could not be definitively confirmed in any of the 75 cases seen. They also share a case review summary from the Pfizer documents showing 136 post-vaccination fatalities and a conclusion that “This cumulative case review does not raise new safety issues”. Both the FDA and the UK Health Security Agency (HSA) appear to be complicit in assisting Pfizer with ongoing duplicity. FDA approved emergency use authorisation of these injections despite being aware of the high rates of serious adverse events. The HSA removed hospitalisation and death rates of the double-vaccinated population from surveillance reports, helping to obscure evidence of VAED.
This raises questions about what other data has been obscured by false conclusions or dishonest data presentations? Journalist and author Dr Naomi Wolf is working with teams of qualified volunteer researchers to investigate the Pfizer trial data as it is released. Their work can be found at The Daily Clout.
One of the basic tenets of public health is honest and transparent messaging to foster trusting relationships between health services and the public. Once a business model is introduced, prioritising profits and power over medical ethics, public health as a societal goal and as a professional discipline is quickly shattered.